| Name | Title | Contact Details |
|---|
Armo Biosciences is a company based out of 1630 Channing Ave, Palo Alto, California, United States.
For nearly 50 years, Acts Retirement-Life Communities has met the retirement lifestyle and healthcare needs of older adults living in our communities. Our first community opened in 1972 with the vision of a church pastor and his congregation whose goal was to create an environment that offered seniors a rewarding lifestyle and high quality healthcare if ever needed. Today, Acts is the largest not-for-profit owner, operator and developer of continuing care retirement communities (CCRCs) in the United States. Our 26 communities currently serve more than 10,000 residents in nine states. Our vision for Acts is to have The Acts Culture of Loving-Kindness be the basic fiber of our daily practice to meet the needs of those we serve. As we continue to grow, we`re looking for dedicated and compassionate individuals to join our team who help to carry out our mission of serving older adults. We have been able to provide an unparalleled quality of life for our residents by recruiting and hiring great people who understand our vision and strive to be a part of it. We are convinced that the secret to our success is our employees who work as a team each day to make a positive difference in the lives of our residents. It is for this reason that we provide a working environment based on fair employment practices, competitive pay and benefits, career opportunities and other programs designed to help our employee`s achieve their professional goals.
Small Bone Innovations, LLC (Main) Corp HQ is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Small Bone Innovations, LLC (Main) Corp HQ is based in New York, NY. You can find more information on Small Bone Innovations, LLC (Main) Corp HQ at www.totalsmallbone.com
Wolters Kluwer Health is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.